PROBING EBV-LMP-1'S TRANSMEMBRANE ACTIVATION DOMAIN WITH SYNTHETIC PEPTIDE ANTAG

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 尽管存在许多针对从外部可访问的分子靶点的治疗策略 细胞内(如治疗性抗体)或细胞质内(如小分子 抑制剂)，它们不适用于位于膜双层内的分子靶标。 疏水磷脂双层对水溶极性施加了一道无法穿透的屏障 治疗剂。我们正在探索EB病毒-LMP-1‘S跨膜激活结构域 合成肽拮抗剂，试图寻找新的LMP-1复合体。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Although many therapeutic strategies exist for molecular targets accessible from the outside of the cell (e.g. therapeutic antibodies) or within the cytoplasm (e.g. small molecule inhibitors), they are not applicable to molecular targets that lie within the membrane bilayer. The hydrophobic phospholipid bilayer imposes an impenetrable barrier to water-soluble polar therapeutic agents. We are probing EBV-LMP-1's Transmembrane Activation Domain with Synthetic Peptide Antagonist in attempt to find novel LMP-1 complexes.